-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
May 20 is a romantic d.
According to wind statistics, on May 20, a total of 891 stocks received net purchases through financing, of which 13 stocks with net purchases exceeding 100 million yuan, and there are many pharmaceutical stoc.
From the perspective of individual stocks, Shanghai Pharmaceuticals ranks first in net purchases of financi.
The stock’s financing and securities lending data show that on May 20, the financing purchased 526 million yuan, the financing repayment was 247 million yuan, the financing net purchase was 279 million yuan, and the current financing balance was 486 billion yuan; 10,000 shares, 198,600 shares were repaid by securities lending, and a net sale of 968,600 shares from securities lendi.
The current balance of securities lending is 3,596,100 shar.
On the whole, the balance of margin financing and securities lending of Shanghai Pharmaceuticals on May 20 increased by RMB 300 million to RMB 555 billion compared with that on the 19.
According to the data, Shanghai Pharmaceuticals is a large domestic pharmaceutical industry gro.
The company's main business covers the pharmaceutical industry, distribution and reta.
Among them, pharmaceutical business revenue is the company's main source of reven.
In 2021, the revenue of this sector will reach 197 billion yuan, a year-on-year increase of 14
It is worth mentioning that Shanghai Pharmaceuticals will launch a 10 billion-level fixed increase project in 2021, and plans to introduce Yunnan Baiyao as a strategic invest.
After the issuance, Yunnan Baiyao will become the second largest shareholder of Shanghai Pharmaceuticals, bringing new momentum to the long-term development of Shanghai Pharmaceutica.
At the same time, Shanghai Pharmaceuticals will also cooperate with Yunnan Baiyao to carry out business synergy and jointly build a business platform for traditional Chinese medicine and big heal.
In terms of the distribution of traditional Chinese medicine, the scale of the traditional Chinese medicine business segment of Shanghai Pharmaceuticals has exceeded 7 billion yuan, and it has 7 key Chinese medicine enterprises including Shanghai Pharma, Huqingyutang Pharmaceutical, and Chia Tai Qingchunbao, 3 nationally confidential formulas, as well as Shenxiang, Lei, e.
9 well-recognized core brands, including Qingchunbao, Huqingyutang,e.
In addition to Shanghai Pharmaceuticals, the top pharmaceutical stocks in terms of financing net purchases on the day include Huahai Pharmaceutical, Junshi Bio and other stocks, with net purchases exceeding 100 million yu.
According to the data of Huahai Pharmaceutical’s margin financing and securities lending, on May 20, the financing purchased 355 million yuan, the financing repayment was 197 million yuan, the financing net purchase was 158 million yuan, and the current financing balance was 041 billion yuan; 625,600 shares were sold, 246,300 shares were repaid by securities lending, and a net sale of 379,300 shares from securities lendi.
The current balance of securities lending is 2,457,900 shar.
On the whole, Huahai Pharmaceutical's balance of margin financing and securities lending on May 20 increased by 170 million yuan to 092 billion yuan from the previous d.
According to the data, Huahai Pharmaceutical is mainly engaged in the R&D, production and sales of multi-dose generic drugs, biological drugs, innovative drugs and specialty AP.
It is a company integrating pharmaceutical R&D, manufacturing and sal.
Junshi Bio’s margin financing and securities lending data show that on May 20, the financing purchased 398 million yuan, the financing repayment was 297 million yuan, the financing net purchase was 100 million yuan, and the current financing balance was 168 billion yuan; 432,000 shares were sold, 283,100 shares were repaid by securities lending, and a net sale of 148,900 shares from securities lendi.
The current balance of securities lending is 4,755,700 shar.
On the whole, Junshi Bio's margin financing and securities lending balance on May 20 increased by 102 million yuan to 700 billion yuan from the previous d.
According to the data, Junshi Bio is an innovation-driven biopharmaceutical compa.
The company's main business is the research and development of new drugs, the transfer and service of related technologies, and the production and sales of new dru.
Its main products include toripalimab injection, Telvezumab, Adalimumab injection, e.
are used for the treatment of malignant tumors, autoimmune system diseases, nervous system diseases and infectious diseas.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
According to wind statistics, on May 20, a total of 891 stocks received net purchases through financing, of which 13 stocks with net purchases exceeding 100 million yuan, and there are many pharmaceutical stoc.
From the perspective of individual stocks, Shanghai Pharmaceuticals ranks first in net purchases of financi.
The stock’s financing and securities lending data show that on May 20, the financing purchased 526 million yuan, the financing repayment was 247 million yuan, the financing net purchase was 279 million yuan, and the current financing balance was 486 billion yuan; 10,000 shares, 198,600 shares were repaid by securities lending, and a net sale of 968,600 shares from securities lendi.
The current balance of securities lending is 3,596,100 shar.
On the whole, the balance of margin financing and securities lending of Shanghai Pharmaceuticals on May 20 increased by RMB 300 million to RMB 555 billion compared with that on the 19.
According to the data, Shanghai Pharmaceuticals is a large domestic pharmaceutical industry gro.
The company's main business covers the pharmaceutical industry, distribution and reta.
Among them, pharmaceutical business revenue is the company's main source of reven.
In 2021, the revenue of this sector will reach 197 billion yuan, a year-on-year increase of 14
It is worth mentioning that Shanghai Pharmaceuticals will launch a 10 billion-level fixed increase project in 2021, and plans to introduce Yunnan Baiyao as a strategic invest.
After the issuance, Yunnan Baiyao will become the second largest shareholder of Shanghai Pharmaceuticals, bringing new momentum to the long-term development of Shanghai Pharmaceutica.
At the same time, Shanghai Pharmaceuticals will also cooperate with Yunnan Baiyao to carry out business synergy and jointly build a business platform for traditional Chinese medicine and big heal.
In terms of the distribution of traditional Chinese medicine, the scale of the traditional Chinese medicine business segment of Shanghai Pharmaceuticals has exceeded 7 billion yuan, and it has 7 key Chinese medicine enterprises including Shanghai Pharma, Huqingyutang Pharmaceutical, and Chia Tai Qingchunbao, 3 nationally confidential formulas, as well as Shenxiang, Lei, e.
9 well-recognized core brands, including Qingchunbao, Huqingyutang,e.
In addition to Shanghai Pharmaceuticals, the top pharmaceutical stocks in terms of financing net purchases on the day include Huahai Pharmaceutical, Junshi Bio and other stocks, with net purchases exceeding 100 million yu.
According to the data of Huahai Pharmaceutical’s margin financing and securities lending, on May 20, the financing purchased 355 million yuan, the financing repayment was 197 million yuan, the financing net purchase was 158 million yuan, and the current financing balance was 041 billion yuan; 625,600 shares were sold, 246,300 shares were repaid by securities lending, and a net sale of 379,300 shares from securities lendi.
The current balance of securities lending is 2,457,900 shar.
On the whole, Huahai Pharmaceutical's balance of margin financing and securities lending on May 20 increased by 170 million yuan to 092 billion yuan from the previous d.
According to the data, Huahai Pharmaceutical is mainly engaged in the R&D, production and sales of multi-dose generic drugs, biological drugs, innovative drugs and specialty AP.
It is a company integrating pharmaceutical R&D, manufacturing and sal.
Junshi Bio’s margin financing and securities lending data show that on May 20, the financing purchased 398 million yuan, the financing repayment was 297 million yuan, the financing net purchase was 100 million yuan, and the current financing balance was 168 billion yuan; 432,000 shares were sold, 283,100 shares were repaid by securities lending, and a net sale of 148,900 shares from securities lendi.
The current balance of securities lending is 4,755,700 shar.
On the whole, Junshi Bio's margin financing and securities lending balance on May 20 increased by 102 million yuan to 700 billion yuan from the previous d.
According to the data, Junshi Bio is an innovation-driven biopharmaceutical compa.
The company's main business is the research and development of new drugs, the transfer and service of related technologies, and the production and sales of new dru.
Its main products include toripalimab injection, Telvezumab, Adalimumab injection, e.
are used for the treatment of malignant tumors, autoimmune system diseases, nervous system diseases and infectious diseas.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
